MX2023013225A - Inhibidores de la cinasa 4 similar a polo. - Google Patents

Inhibidores de la cinasa 4 similar a polo.

Info

Publication number
MX2023013225A
MX2023013225A MX2023013225A MX2023013225A MX2023013225A MX 2023013225 A MX2023013225 A MX 2023013225A MX 2023013225 A MX2023013225 A MX 2023013225A MX 2023013225 A MX2023013225 A MX 2023013225A MX 2023013225 A MX2023013225 A MX 2023013225A
Authority
MX
Mexico
Prior art keywords
formula
pharmaceutically acceptable
polo
kinase
inhibitors
Prior art date
Application number
MX2023013225A
Other languages
English (en)
Inventor
Hong Wang
Chudi Ndubaku
Stephane Ciblat
Hiroyuki Kawai
Xiaohui Du
Lea Constantineau-Forget
F Anthony Romero
Vincent Albert
Kejia Wu
Joanne Tan
Jared Thomas Moore
Paul Anthony Gibbons
Jae Hyuk Chang
Hugo De Almeida Silva
Dilan Emine Polat
Amit Nayyar
Daniel Gordon Michael Shore
Original Assignee
Oric Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oric Pharmaceuticals Inc filed Critical Oric Pharmaceuticals Inc
Publication of MX2023013225A publication Critical patent/MX2023013225A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
    • C07F9/5325—Aromatic phosphine oxides or thioxides (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente se describen compuestos de la Fórmula (I), o sales farmacéuticamente aceptables de los mismos, que son inhibidores de Cinasa 4 Similar a Polo (PLK4). También se describen en la presente composiciones farmacéuticas que comprenden los compuestos de la Fórmula (I), o sales farmacéuticamente aceptables de los mismos, y uno o más excipientes farmacéuticamente aceptables. En la presente se describen además métodos para tratar el cáncer en un sujeto en necesidad del mismo, que comprenden administrar al sujeto una cantidad de un compuesto de la Fórmula (I), o una sal farmacéuticamente aceptable del mismo. (ver formula).
MX2023013225A 2021-05-11 2022-05-10 Inhibidores de la cinasa 4 similar a polo. MX2023013225A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163187049P 2021-05-11 2021-05-11
US202163249809P 2021-09-29 2021-09-29
US202263317174P 2022-03-07 2022-03-07
US202263337445P 2022-05-02 2022-05-02
PCT/US2022/028594 WO2022240876A1 (en) 2021-05-11 2022-05-10 Polo like kinase 4 inhibitors

Publications (1)

Publication Number Publication Date
MX2023013225A true MX2023013225A (es) 2024-01-15

Family

ID=84029392

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013225A MX2023013225A (es) 2021-05-11 2022-05-10 Inhibidores de la cinasa 4 similar a polo.

Country Status (10)

Country Link
US (2) US11858915B2 (es)
EP (1) EP4337198A1 (es)
JP (1) JP2024521657A (es)
KR (1) KR20240035390A (es)
AU (1) AU2022272184A1 (es)
CA (1) CA3217983A1 (es)
IL (1) IL308346A (es)
MX (1) MX2023013225A (es)
TW (1) TW202309008A (es)
WO (1) WO2022240876A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL308346A (en) 2021-05-11 2024-01-01 Oric Pharmaceuticals Inc POLO-like kinase 4 inhibitors
WO2024076891A1 (en) * 2022-10-03 2024-04-11 Oric Pharmaceuticals, Inc. Polo like kinase 4 inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2265452T3 (es) 2000-12-21 2007-02-16 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de la proteina quinasa.
EP2235004A4 (en) 2007-12-21 2011-05-04 Univ Health Network INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT
CA2756568C (en) 2009-04-06 2018-02-13 University Health Network Kinase inhibitors and method of treating cancer with same
CN102892766B (zh) 2010-04-06 2015-05-20 大学健康网络 激酶抑制剂和用其治疗癌症的方法
WO2011123937A1 (en) 2010-04-06 2011-10-13 University Health Network Kinase inhibitors and method of treating cancer with same
WO2012000103A1 (en) 2010-07-02 2012-01-05 University Health Network Methods of targeting pten mutant diseases and compositions therefor
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
WO2013050508A1 (en) 2011-10-07 2013-04-11 Cellzome Limited Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mtor inhibitors
US20140051679A1 (en) 2011-10-12 2014-02-20 Univeristy Health Networks Kinase inhibitors and method of treating cancer with same
WO2014056083A1 (en) 2012-10-12 2014-04-17 University Health Network Kinase inhibitors and method of treating cancer with same
US9642856B2 (en) 2013-10-18 2017-05-09 University Health Network Treatment for pancreatic cancer
HUE043194T2 (hu) 2013-10-18 2019-08-28 Univ Health Network PLK-4 inhibitor sója és kristályformái
EA032754B1 (ru) 2013-11-01 2019-07-31 Новартис Аг Аминогетероарил бензамиды в качестве ингибиторов киназы
EP3283482B1 (en) 2015-04-17 2022-04-06 Ludwig Institute for Cancer Research Ltd Plk4 inhibitors
WO2017028314A1 (en) 2015-08-20 2017-02-23 Changzhou Jiekai Pharmatech Co., Ltd. Pyrazolo fused heterocyclic compounds as erk inhibitors
CN108602805A (zh) 2015-10-29 2018-09-28 效应治疗股份有限公司 Mnk1和mnk2的异吲哚啉、氮杂异吲哚啉、二氢茚酮和二氢氮杂茚酮抑制剂
US20180369214A1 (en) 2017-06-27 2018-12-27 Emory University Methods of Diagnosing and Treating Small Cell Lung Cancer Using Polo-Like Kinase 1 (PLK1) Inhibitors
CN111225670A (zh) 2017-09-08 2020-06-02 大学健康网络 抑制Polo样激酶4的组合疗法
US11612604B2 (en) 2017-12-06 2023-03-28 Ludwig Institute For Cancer Research Ltd Methods of treating cancer with PLK4 inhibitors
BR112021021106A2 (pt) 2019-04-24 2021-12-14 Univ Health Network Forma cristalina s4 do inibidor plk4 fumarato (ir,2s)-(e)-2-(3-(4-((cis-2,6-dimetilmorfolino)metil)estiril)-1h-imidazol-6-il)-5'-metoxiespiro[ciclopropano-1,3'-indolin]-2'ona
MX2022006910A (es) 2019-12-06 2022-11-09 Univ Health Network Tratamiento para la leucemia mieloide aguda o para el síndrome mielodisplásico.
US20230165871A1 (en) 2020-04-06 2023-06-01 University Health Network Combination therapies for inhibition of polo-like kinase 4
CN112225729B (zh) 2020-11-04 2022-02-01 四川大学华西医院 嘧啶类衍生物、其制备方法和应用以及药物组合物
TW202300485A (zh) 2021-03-02 2023-01-01 大陸商上海齊魯製藥研究中心有限公司 Plk4抑制劑及其用途
IL308346A (en) 2021-05-11 2024-01-01 Oric Pharmaceuticals Inc POLO-like kinase 4 inhibitors
CN115677682B (zh) 2021-07-30 2023-07-18 上海齐鲁制药研究中心有限公司 螺环类plk4抑制剂及其用途

Also Published As

Publication number Publication date
US11858915B2 (en) 2024-01-02
CA3217983A1 (en) 2022-11-17
EP4337198A1 (en) 2024-03-20
US20240124426A1 (en) 2024-04-18
TW202309008A (zh) 2023-03-01
KR20240035390A (ko) 2024-03-15
AU2022272184A1 (en) 2023-11-30
WO2022240876A1 (en) 2022-11-17
IL308346A (en) 2024-01-01
JP2024521657A (ja) 2024-06-04
US20230365537A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
WO2020106647A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2023007192A (es) Inhibidores de prmt5.
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
CR20220230A (es) Inhibidores de pequeñas moléculas de mutante g12c de kras
MX2023013225A (es) Inhibidores de la cinasa 4 similar a polo.
MX2023005984A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
CR20230286A (es) Inhibidores de prmt5 novedosos
ZA202202325B (en) Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
MX2023005983A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
MX2023001756A (es) Peptidos funcionalizados como agentes antivirales.
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
MX2022012056A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento.
MX2023001298A (es) Combinaciones para el tratamiento de cancer.
MX2022004808A (es) Métodos para tratar el cáncer de próstata.
MX2022004197A (es) Inhibidores del factor d del complemento para administracion oral.
MX2022001743A (es) Formas en estado solido de (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahi dronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2- il)-1h-imidazol-4-il)pentanamida y usos de la misma.
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
JOP20220077A1 (ar) مثبطات عامل d المكمل عن طريق الفم
MX2022014192A (es) Metodos para tratar el cancer de prostata.
MX2021015447A (es) Métodos de tratamiento del cáncer dirigidos a tumores fríos.